Hope Medicine
Latest round
- Series B
Last raised
- Feb 2024
Total raised
- $84M
Investors
- 10
About Hope Medicine
Established in 2018 and based in Shanghai, China, Hope Medicine is a biopharmaceutical company that focuses on the development of drugs targeting prolactin receptors and novel antibodies. It has partnerships with Nanjing JiangBei New Area, Bayer, and other companies. The research and development bases and offices have been set up in Beijing, Shanghai, and Nanjing. The founder and CSO, Ruiping Xiao, is the founding director and chair professor of the Institute of Molecular Medicine of Peking University. In 2022, HMI-115 has been approved for Phase II clinical trials in China for the treatment of endometriosis. The company is committed to the research, development, and industrialization of prolactin. It has developed a potential first-in-class human antibody (HMI-115) targeting the prolactin receptor, which can be used for the treatment of endometriosis, androgenic alopecia, and other diseases with dysregulated prolactin signaling. The pipelines also include GPCR antagonists, Kinase inhibitors, etc. The company will use the series B+ funds for the research and development of the core pipeline, HMI-115 monoclonal antibody, two ongoing international clinical phase II studies, and other product lines.
Who invested in Hope Medicine
10 investors across 3 rounds
See all investors in Hope Medicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hope Medicine
Who invested in Hope Medicine?
Hope Medicine has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hope Medicine raised?
Hope Medicine has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Hope Medicine last raise money?
Hope Medicine's most recent round on record is a Series B, in Feb 2024.
What does Hope Medicine do?
Established in 2018 and based in Shanghai, China, Hope Medicine is a biopharmaceutical company that focuses on the development of drugs targeting prolactin receptors and novel antibodies.
Where is Hope Medicine headquartered?
Hope Medicine is headquartered in Shanghai, China.
Which VCs invest in companies like Hope Medicine?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Hope Medicine's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Hope Medicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.